https://doi.org/10.46344/JBINO.2025.v14i03.25

NITROGEN-BASED THERAPEUTICS: A NEW HORIZON IN SICKLE CELL ANEMIA TREATMENT

***Emmanuel Ifeanyi Obeagu**

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, E-mail: emmanuelobeagu@yahoo.com, obeague@africau.edu, ORCID: 0000-0002-4538-0161

ABSTRACT

Sickle Cell Anemia (SCA) is a chronic hemoglobinopathy marked by recurrent vaso-occlusive episodes, hemolysis, and systemic complications resulting from the polymerization of deoxygenated hemoglobin S. Despite advancements in conventional therapies such as hydroxyurea and transfusion protocols, the disease continues to pose substantial clinical challenges, particularly in resource-limited settings. Among emerging therapeutic strategies, nitrogen-based interventions—particularly those involving nitric oxide (NO)—have garnered significant attention for their capacity to restore vascular homeostasis and mitigate endothelial dysfunction, which are central features of SCA pathophysiology. Nitric oxide plays a pivotal role in vasodilation, inhibition of platelet aggregation, and modulation of leukocyte adhesion. In SCA, chronic hemolysis depletes endogenous NO through scavenging by free hemoglobin, contributing to vasoconstriction, inflammation, and oxidative stress. Therapeutic approaches such as inhaled NO, L-arginine supplementation, nitrite/nitrate therapies, and hydroxyurea—recognized for its dual role as a fetal hemoglobin inducer and NO donor—have been explored for their capacity to counteract NO depletion and improve clinical outcomes.

Keywords: Sickle Cell Anemia, Nitric Oxide, Hemoglobin S, Vaso-occlusion, Nitrogen-Based Therapy

Introduction

Sickle Cell Anemia (SCA) is a genetically inherited disorder caused by a point mutation in the β-globin gene, leading to the production of abnormal hemoglobin S (HbS). Under hypoxic conditions, HbS polymerizes, causing erythrocytes to adopt a rigid, sickle-like shape. These deformed cells are prone to hemolysis and can obstruct capillary blood flow, resulting in vaso-occlusive crises (VOCs), chronic pain, ischemia-reperfusion injury, and cumulative organ damage. SCA affects millions globally, with the highest prevalence in sub-Saharan Africa, the Middle East, and India, and presents a significant burden on healthcare systems [1-3]. Over the years, various treatment options have been employed to manage SCA, including hydroxyurea therapy, chronic transfusions, pain management, and, in some cases, hematopoietic stem cell transplantation. Hydroxyurea remains the mainstay of pharmacologic therapy and functions by increasing fetal hemoglobin (HbF) levels, thereby reducing sickling. However, not all patients respond optimally, and long-term use may be associated with adverse effects or poor adherence, especially in resource-limited settings. This underscores the pressing need for adjunct or alternative therapies that target different aspects of SCA pathophysiology [5-6].

One of the critical factors implicated in the vascular complications of SCA is nitric oxide (NO) deficiency. Nitric oxide is an endogenously produced gasotransmitter synthesized by nitric oxide synthase (NOS) from L-arginine. It plays a crucial role in maintaining vascular tone, inhibiting platelet aggregation, and suppressing adhesion of leukocytes to the endothelium. In individuals with SCA, chronic intravascular hemolysis releases cell-free hemoglobin into the plasma, this rapidly scavenges NO, reducing its bioavailability and contributing to a state of vasculopathy and inflammation [7-8]. The link between NO deficiency and the clinical manifestations of SCA has led to the exploration of nitrogen-based therapeutics, particularly agents aimed at enhancing NO production or mimicking its function. These include inhaled nitric oxide, L-arginine and L-citrulline supplementation, nitrate/nitrite-based drugs, and agents like hydroxyurea that modulate NO pathways indirectly. These therapeutics aim to restore NO levels in the vasculature, thereby alleviating endothelial dysfunction and potentially reducing the frequency and severity of VOCs [9-10]. Clinical studies and experimental trials have demonstrated varying degrees of success with nitrogen-based interventions. Some have shown improvements in endothelial function, decreased inflammation, and better oxygen delivery. However, challenges such as short half-life of NO, delivery mechanisms, inter-patient variability, and risks of oxidative stress have tempered early enthusiasm. Nevertheless, the biologic plausibility and preliminary clinical data support continued investigation into nitrogen-based therapies as promising adjuncts in SCA treatment [11-13].

Pathophysiological Role of Nitric Oxide in Sickle Cell Anemia

Nitric oxide (NO) is a critical signaling molecule synthesized by endothelial nitric

oxide synthase (eNOS) from its substrate L-arginine. It plays a vital role in maintaining vascular homeostasis by promoting vasodilation, inhibiting platelet aggregation, and preventing leukocyte and erythrocyte adhesion to the endothelium. In the context of Sickle Cell Anemia (SCA), the homeostatic function of NO is severely disrupted, contributing significantly to the vascular and inflammatory complications characteristic of the disease [14-16]. In SCA, chronic intravascular hemolysis leads to the continuous release of free hemoglobin into the plasma. This cell-free hemoglobin avidly binds and inactivates NO through a rapid chemical reaction, forming methemoglobin and nitrate. The result is a marked reduction in NO bioavailability, leading to vasoconstriction and impaired regulation of blood flow. Moreover, the hemolysis-associated release of arginase from red blood cells further depletes plasma L-arginine—the precursor for NO synthesis—thereby compounding the deficit in NO production [17-19]. This nitric oxide deficiency has downstream consequences that exacerbate the clinical severity of SCA. The reduction in NO levels promotes endothelial dysfunction, a pro-inflammatory state, and increased expression of adhesion molecules such as VCAM-1, ICAM-1, and E-selectin. These changes facilitate the adhesion of sickled erythrocytes, activated leukocytes, and platelets to the vascular endothelium, thereby initiating and perpetuating vaso-occlusive episodes. These interactions are central to the pathophysiology of pain crises, acute chest syndrome, and other ischemic complications observed in SCA [20-22].

Furthermore, reduced NO levels contribute to pulmonary hypertension, a common and severe complication of SCA associated with increased morbidity and mortality. NO plays a pivotal role in maintaining low pulmonary vascular resistance; its depletion results in vasoconstriction and vascular remodeling, thereby elevating pulmonary artery pressures. Patients with low hemolytic markers often show better NO metabolism, further supporting the link between hemolysis and NO deficiency [23]. Another important consequence of NO depletion is the impairment of oxygen delivery. NO facilitates the release of oxygen from hemoglobin and improves red blood cell deformability—an essential function compromised in SCA. Without adequate NO, sickled cells become less flexible and more likely to obstruct microvasculature, exacerbating tissue hypoxia and oxidative stress. This creates a vicious cycle wherein hypoxia and hemolysis perpetuate NO depletion and vascular injury [24].

Nitrogen-Based Therapeutics: Mechanisms and Agents

The pursuit of nitrogen-based therapeutics in Sickle Cell Anemia (SCA) arises from the central role of nitric oxide (NO) depletion in disease pathogenesis. These agents aim to restore vascular NO levels, improve endothelial function, and alleviate downstream complications such as vaso-occlusion and oxidative stress. Mechanistically, nitrogen-based therapeutics exert their effects through three principal pathways: NO supplementation, NO precursor availability,

and NO-mimetic pharmacodynamics [25-26].

Inhaled Nitric Oxide (iNO) is a direct method of supplementing NO to the pulmonary vasculature. As a selective pulmonary vasodilator, iNO has shown potential in alleviating acute complications such as acute chest syndrome by reducing pulmonary artery pressures and improving oxygenation. However, clinical trials have yielded mixed results, with some failing to demonstrate significant reductions in pain duration or hospitalization time. The transient nature of iNO's effects, challenges in sustained delivery, and its inactivation by circulating oxyhemoglobin have limited its broader therapeutic application [27-28].

L-Arginine and L-Citrulline supplementation represent strategies to enhance endogenous NO production. L-arginine is the substrate for endothelial nitric oxide synthase (eNOS), while L-citrulline is a precursor that recycles back to L-arginine via the urea cycle. In SCA patients, hemolysis-related arginase release depletes L-arginine, thereby impairing NO synthesis. Supplementing these amino acids has been shown to improve endothelial function, reduce pulmonary hypertension, and decrease the frequency of vaso-occlusive episodes in some studies. Nevertheless, the efficacy is often modulated by factors such as individual metabolic status, dosing regimens, and disease severity [29-30].

Nitrite and nitrate-based therapies are emerging as novel modalities in NO restoration. These inorganic nitrogen oxides can be converted to NO under hypoxic conditions through enzymatic and non-enzymatic pathways. This feature is particularly advantageous in SCA, where ischemia and hypoxia prevail. Sodium nitrite has been shown in preclinical models to improve blood flow and reduce inflammation. Clinical trials in humans are ongoing, with some evidence suggesting enhanced exercise tolerance and decreased vascular stiffness. However, careful monitoring is required due to risks of methemoglobinemia and hypotension [31-33].

Hydroxyurea, the most widely used disease-modifying agent in SCA, also exerts indirect NO-related effects. In addition to inducing fetal hemoglobin (HbF), hydroxyurea is believed to increase NO production via chemical decomposition and modulation of eNOS activity. These NO-mediated effects contribute to its ability to improve red cell deformability, decrease leukocyte adhesion, and enhance vascular function. Its dual role as an NO donor and HbF inducer underscores the multifaceted nature of nitrogen-based interventions [34-35].

Novel NO-donating compounds, such as S-nitrosothiols and NO-releasing prodrugs, are under investigation. These agents are designed for controlled NO release with minimal systemic toxicity. While still in early phases of development, they offer promise for targeted therapy with improved pharmacokinetics. Additionally, hybrid molecules combining NO-donor functions with anti-inflammatory or antioxidant properties may offer synergistic benefits in SCA management [36-37].

Conclusion

Nitrogen-based therapeutics represent a promising and innovative frontier in the

management of Sickle Cell Anemia (SCA), targeting one of the core pathophysiological disruptions—nitric oxide deficiency and endothelial dysfunction. From direct nitric oxide supplementation and precursor amino acid therapy to novel nitrite and nitrate-based agents, these approaches aim to restore vascular homeostasis, alleviate vaso-occlusion, and improve overall clinical outcomes. While current evidence from clinical trials reveals encouraging trends, particularly with L-arginine and L-citrulline, inconsistencies in therapeutic efficacy, delivery methods, and patient responses underscore the need for further investigation. The integration of these agents into standard SCA treatment regimens requires well-designed, large-scale clinical studies to clarify optimal dosing, treatment duration, and safety profiles. Moreover, personalized medicine approaches that account for individual metabolic and genetic variability may enhance the therapeutic benefits of nitrogen-based interventions.

References

1. Gupta A. Sickle Cell Anemia and Related Hemoglobinopathies. InDecision Making Through Problem Based Learning in Hematology: A Step-by-Step Approach in patients with Anemia 2024: 269-289. Singapore: Springer Nature Singapore.
2. Hassan MS, Nasrin T, Mahalka A, Hoque M, Ali S. A perspective on the genesis, diagnostics, and management of sickle cell disease. Egyptian Journal of Medical Human Genetics. 2024; 25(1):150.
3. Rajput HS, Kumari M, Talele C, Sajan C, Saggu V, Hadia R. Comprehensive Overview Of Sickle Cell Disease: Global Impact, Management Strategies, And Future Directions. Journal of Advanced Zoology. 2024; 45(1).
4. Obeagu EI. Role of Autophagy in Modulating Oxidative Stress in Sickle Cell Disease: A Narrative Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):38-46.
5. Obeagu EI. Redox Regulation of Hemoglobin in Sickle Cell Disease: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):13-9.
6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. Int Res Med Health Sci. 2023 Sep 11;6:12-7.
7. Xiao R, Li L, Zhang Y, Fang L, Li R, Song D, Liang T, Su X. Reducing carbon and nitrogen loss by shortening the composting duration based on seed germination index (SCD@ GI): feasibilities and challenges. Science of The Total Environment. 2024:172883.
8. Lin W, Lv X, Wang Q, Li L, Zou G. Nitrogen concentration dependent optical defects transition in single crystal diamond through low pressure high temperature annealing. Vacuum. 2025:114329.
9. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clinical & Experimental Pharmacology & Physiology. 2007 Sep 1;34(9).
10. Dijkmans T, Djokic MR, Van Geem KM, Marin GB. Comprehensive compositional analysis of sulfur and nitrogen containing compounds in shale oil using GC× GC–FID/SCD/NCD/TOF-MS. Fuel. 2015; 140:398-406.
11. Muehle M, Asmussen J, Becker MF, Schuelke T. Extending microwave plasma

assisted CVD SCD growth to pressures of 400 Torr. Diamond and Related Materials. 2017; 79:150-163.
12. Obeagu EI, Obeagu GU. Immunization strategies for individuals with sickle cell anemia: A narrative review. Medicine. 2024; 103(38):e39756.
13. Obeagu EI. Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. Annals of Medicine and Surgery.:10-97.
14. Obeagu EI. Erythropoeitin in sickle cell anaemia: a review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
15. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: prevalence, impact, and interventions: a review. Medicine. 2024 May 17;103(20):e38164.
16. Quemada M, Delgado A, Mateos L, Villalobos FJ. Nitrogen fertilization I: The nitrogen balance. InPrinciples of agronomy for sustainable agriculture 2024: 377-401. Cham: Springer International Publishing.
17. Krug EC, Winstanley D. The need for comprehensive and consistent treatment of the nitrogen cycle in nitrogen cycling and mass balance studies: I. Terrestrial nitrogen cycle. Science of the total environment. 2002; 293(1-3):1-29.
18. Zhang CC, Zhou CZ, Burnap RL, Peng L. Carbon/nitrogen metabolic balance: lessons from cyanobacteria. Trends in plant science. 2018; 23(12):1116-1130.
19. Enwonwu CO, Xu XX, Turner E. Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. The American journal of the medical sciences. 1990; 300(6):366-371.
20. Borel MJ, Buchowski MS, Turner EA, Peeler BB, Goldstein RE, Flakoll PJ. Alterations in basal nutrient metabolism increase resting energy expenditure in sickle cell disease. American Journal of Physiology-Endocrinology and Metabolism. 1998; 274(2):E357-364.
21. Jackson AA. The use of stable isotopes to study nitrogen metabolism in homozygous sickle cell disease. InGenetic factors in nutrition. 1984: 297-315. Academic Press, New York.
22. Schnog JJ, Jager EH, van der Dijs FP, Duits AJ, Moshage H, Muskiet FD, Muskiet FA. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Annals of Hematology. 2004; 83:371-375.
23. Darghouth D, Koehl B, Madalinski G, Heilier JF, Bovee P, Xu Y, Olivier MF, Bartolucci P, Benkerrou M, Pissard S, Colin Y. Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome. Blood, The Journal of the American Society of Hematology. 2011; 117(6):e57-66.
24. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. Jama. 2005; 294(1):81-90.
25. Zhou Y, Yu X, Nicely A, Cunningham G, Challa C, McKinley K, Nickel R, Campbell A, Darbari D, Summar M, Majumdar S. Amino acid signature during sickle cell pain crisis shows significant alterations related to nitric oxide and energy metabolism. Molecular genetics and metabolism. 2022; 137(1-2):146-152.
26. D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM,

Gordeuk VR. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment. Haematologica. 2023; 108(12):3418.
27. Obeagu EI, Obeagu GU. Management of diabetes mellitus patients with sickle cell anemia: challenges and therapeutic approaches. Medicine. 2024; 103(17):e37941.
28. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review. Current Research in Biological Sciences. 2025;1(1):01-8.
29. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: diarrhea in sickle cell anemia. Medicine. 2024; 103(18):e38075.
30. Obeagu EI, Obeagu GU. Living with sickle cell in Uganda: A comprehensive perspective on challenges, coping strategies, and health interventions. Medicine. 2024 Dec 20;103(51):e41062.
31. Obeagu EI, Adias TC, Obeagu GU. Advancing life: innovative approaches to enhance survival in sickle cell anemia patients. Annals of Medicine and Surgery. 2024; 86(10):6021-6036.
32. Bell V, Varzakas T, Psaltopoulou T, Fernandes T. Sickle cell disease update: new treatments and challenging nutritional interventions. Nutrients. 2024; 16(2):258.
33. Khan SA, Damanhouri G, Ali A, Khan SA, Khan A, Bakillah A, Marouf S, Al Harbi G, Halawani SH, Makki A. Precipitating factors and targeted therapies in combating the perils of sickle cell disease---A special nutritional consideration. Nutrition & metabolism. 2016; 13:1-2.
34. Patel S, Patel R, Mukkala SR, Akabari A. Emerging therapies and management approaches in sickle cell disease (SCD): A critical review. Journal of Phytonanotechnology and Pharmaceutical Sciences. 2023; 3(3):1-1.
35. Obeagu EI, Adias TC, Obeagu GU. Advancing life: innovative approaches to enhance survival in sickle cell anemia patients. Annals of Medicine and Surgery. 2024; 86(10):6021-6036.
36. Boma PM, Kaponda AA, Panda J, Bonnechère B. Enhancing the management of pediatric sickle cell disease by integrating functional evaluation to mitigate the burden of vaso-occlusive crises. Journal of Vascular Diseases. 2024; 3(1):77-87.
37. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review. Current Research in Biological Sciences. 2025;1(1):01-8.